Ethics of Cell and Gene Therapy (ECGT) Committee

Charter:

The ISCT Committee on the Ethics of Cell and Gene Therapy (ECGT) strives to:

1. Identify key ethical issues associated with the development, regulatory authorization, marketing, and distribution of cell and gene therapies.
2. Share knowledge and effective strategies among scientific and medical societies, health care providers and institutions, patient associations, and patients and their families.
3. Promote rigorous research, appropriate clinical investigation and application of, and equitable access to cell- and gene-based therapies.

Learn more about Committee Resources - Click here to view

Formerly known as the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies (PTF).

Selected Publications

• International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products (2023)
  
  
• The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy (2022)
  
  
• Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products (2022)
  
  

Committee Chair:

Bruce Levine PhD University of Pennsylvania School of Medicine United States

Committee Vice Chairs: